{"id":60894,"date":"2024-02-28T07:13:40","date_gmt":"2024-02-28T07:13:40","guid":{"rendered":"https:\/\/medsname.com\/hertraz-injection\/"},"modified":"2026-04-30T14:45:56","modified_gmt":"2026-04-30T14:45:56","slug":"hertraz-injection","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nb\/product\/hertraz-injection\/","title":{"rendered":"Hertraz Injection"},"content":{"rendered":"
\n

Kort svar<\/h3>\n

Hertraz Injection<\/strong> er et spesialistoverv\u00e5ket onkologisk middel \u2014 administreres under sykehusoppsyn. Les doserings-, bivirknings- og interaksjonsseksjonene nedenfor f\u00f8r bruk; ofte stilte sp\u00f8rsm\u00e5l finner du nederst.<\/p>\n<\/div>\n

\nHva du f\u00e5r med MedsBase:<\/strong> WHO-GMP-sertifisert produsent \u00b7 Diskret emballasje \u00b7 Verdensomspennende levering \u00b7 1 400+ verifiserte kundeanmeldelser<\/a>\n<\/div>\n

\ud83d\udce6 Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n

Hvorfor bestille fra MedsBase<\/h3>\n

V\u00e5re generiske legemidler kommer fra WHO-GMP-sertifiserte produsenter og sendes over hele verden i diskret, n\u00f8ytral emballasje \u2014 ingen legemiddelnavn p\u00e5 utsiden av pakken. Kortbetalinger h\u00e5ndteres av en regulert betalingsbehandler (kontoutskrifter viser en regulert kortbetalingsprosessor \u2014 aldri \u201cMedsBase\u201d eller noe legemiddelnavn). Krypto og SEPA bankoverf\u00f8rsel godtas ogs\u00e5. Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy.<\/p>\n

Produktoppsummering<\/strong><\/p>\n

Hertraz Injection is a medication containing the active ingredient Trastuzumab, available in vial form with a concentration of 440mg per vial. Trastuzumab is a monoclonal antibody used in the treatment of certain types of cancer, including breast cancer and gastric cancer. It is a targeted therapy that works by binding to specific receptors on cancer cells, inhibiting their growth and promoting cell death. Hertraz Injection is administered intravenously under the supervision of a healthcare professional.<\/p>\n

Bruk<\/strong><\/p>\n

Hertraz Injection is indicated for the treatment of HER2-positive breast cancer, either alone or in combination with other chemotherapy agents. It is also used in combination with other drugs to treat HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-positive cancers overexpress the human epidermal growth factor receptor 2 (HER2), and Trastuzumab specifically targets these receptors to inhibit cancer cell proliferation.<\/p>\n

Bruk anvisning<\/strong><\/p>\n

Hertraz Injection is administered as an intravenous infusion by a healthcare provider in a clinical setting. The dosage and infusion rate are determined based on the patient’s body weight and medical condition. Prior to administration, the vial should be inspected visually for any particulate matter or discoloration. The injection should be given over a specified period, and patients are monitored for any signs of infusion-related reactions during and after the infusion.<\/p>\n

Virkem\u00e5te<\/strong><\/p>\n

Trastuzumab, the active ingredient in Hertraz Injection, is a monoclonal antibody that targets and binds to the HER2 receptors present on the surface of cancer cells. By binding to these receptors, Trastuzumab inhibits downstream signaling pathways that promote cell proliferation and survival. Additionally, it can stimulate the immune system to attack HER2-positive cancer cells, further enhancing its anticancer effects. This targeted approach helps to selectively destroy cancer cells while minimizing damage to healthy tissues.<\/p>\n

Dosering og administrering<\/strong><\/p>\n

The recommended dosage of Hertraz Injection varies depending on the type and stage of cancer being treated, as well as other factors such as the patient’s weight and overall health. It is typically administered intravenously every 1 to 3 weeks, with the dosage adjusted based on the patient’s tolerance and response to treatment. Treatment duration may vary, and patients should follow the dosing schedule recommended by their healthcare provider.<\/p>\n

Fordeler<\/strong><\/p>\n